Objective To observe the different antiviral therapy applied in HBeAg negative chronic hepatitis b patients in the long-term curative effect. Methods 90 cases of HBeAg negative chronic hepatitis B patients into three groups A, B, C, respectively, using lamivudine and adefovir ester and entecavir treatment, compare the curative effect. Results Compared with the treatment of 12 months, 18 months after treatment rate of ALT after often occur significant change (P<0.05). 18 months after treatment, two groups of B, C ALT after constant rate were higher than group A (P<0.05). In terms of HBV-DNA Yin turn, three groups of different time comparison between HBV-DNA Yin turn node group were changed signiifcantly (P<0.05), C group is highest. Compared with the A group for 12 months, the drug resistance rates were significantly changed after 18 months (P<0.05), B, C, two groups of 12 months and 18 months after treatment resistance were not obvious changes (P>0.05). Conclusion Entecavir in the treatment of HBeAg negative chronic hepatitis b has significant advantages, can be used as first-line drugs.%目的：观察不同抗病毒治疗方案应用于HBeAg阴性慢性乙型肝炎患者中的远期疗效。方法将90例HBeAg阴性慢性乙型肝炎患者分成A、B、C三组，分别采用拉米夫定、阿德福韦酯和恩替卡韦治疗，比较其疗效。结果与本组治疗12个月比较，治疗18个月后ALT复常率均发生明显改变（P＜0.05）。治疗18个月后，B、C两组ALT复常率均高于A组（P＜0.05）。在HBV-DNA阴转方面，三组不同时间节点组间比较HBV-DNA阴转均发生显著变化（P＜0.05），C组最高。与A组治疗12个月比较，治疗18个月后耐药率均发生明显改变（P＜0.05）；B、C两组治疗12个月和18个月后耐药率均未发生明显变化（P＞0.05）。结论恩替卡韦治疗HBeAg阴性慢性乙型肝炎有显著优势，可作为一线药物进行选择。
展开▼
